Dateline City:
KENILWORTH, N.J.
Marketing Authorization Application to the European Medicines Agency Currently Under Review
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the New Drug Application (NDA) for MK-1293, an
investigational follow-on biologic1 insulin glargine
candidate for the treatment of people with type 1 and type 2 diabetes,
which is being developed by Merck with partial funding from Samsung
Bioepis.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more